Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy

NCT07414758 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T Cell Lymphoma

Interventions

DRUG: golidocitinib
DRUG: Placebo

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]